Fair value · NOMURA HOLDINGS INC (NMR) · updated 2026-09-03 · from 20-F FY2026
Everything below is unaffected: the filed statements, the filing they came from, and NMR’s growth history are all as reported.
20-F FY2026 · fiscal year ended 2026-03-31 · filed 2026-06-22 · accession 0001193125-26-277134
Open this filing on sec.gov0.22
Put/Call (OI)
call-heavy
0.00
Put/Call (volume)
45%
ATM IV ~30d
$12.5
Call wall
0k OI
$10
Put wall
1k OI
As of previous close (2026-09-02) · OPRA historical data · walls = largest open-interest strikes above/below spot · market-wide positioning
At least two methods need a usable value to draw a range with these inputs.
No preset range for this company yet.
The two ranges are identical because every input sits on a preset.
We don’t tell you what NMR is worth. Every tab OPENS on what today’s price implies for that method’s key assumption; you decide whether that assumption is reasonable — the growth matrix has NMR’s filed history and the AI chat will reason it through with you — and the range you build is yours. Our presets are filed history and reference settings, never a recommendation.
Discounted cash flow
N/A
Financials are filed in JPY; our prices are in USD, so these methods need a conversion we do not yet publish.
Preset inputs — revenue-driven DCF from the latest filing
Implied by today’s price
Financials are filed in JPY; our prices are in USD, so these methods need a conversion we do not yet publish.
Not solvable from the price — Financials are filed in JPY; our prices are in USD, so these methods need a conversion we do not yet publish. Showing preset inputs.
This method has no key input to read out of the price. The others below do, and you set them yourself: the growth matrix shows what NMR has actually filed, and the AI chat will reason it through with you.
Free cash flow grows at your stage-1 rate, then your stage-2 rate, then a terminal rate; everything is discounted at your WACC.
Yearly free-cash-flow growth for the first stage. Starts below zero so a shrinking-cash-flow case — and the rate today’s price implies — can be set.
How long stage-1 growth lasts.
Slower growth after stage 1, before the terminal phase.
Growth forever after the two stages. Above ~3% is rarely justified.
The return you require. Default is the WACC EvidInvest computed for this company. Higher discount rate, lower value.
| Year | Stage | FCF | Present value |
|---|---|---|---|
| 1 | Stage 1 | $-1,256,617M | $-1,143,939M |
| 2 | Stage 1 | $-1,319,448M | $-1,093,433M |
| 3 | Stage 1 | $-1,385,420M | $-1,045,156M |
| 4 | Stage 1 | $-1,454,691M | $-999,012M |
| 5 | Stage 1 | $-1,527,426M | $-954,904M |
| 6 | Stage 2 | $-1,565,611M | $-891,012M |
| 7 | Stage 2 | $-1,604,752M | $-831,395M |
| 8 | Stage 2 | $-1,644,870M | $-775,767M |
| 9 | Stage 2 | $-1,685,992M | $-723,861M |
| 10 | Stage 2 | $-1,728,142M | $-675,428M |
Inputs from the filing
Financials are filed in JPY; our prices are in USD, so these methods need a conversion we do not yet publish.
20-F FY2026 · period ended 2026-03-31 · filed 2026-06-22 · accession 0001193125-26-277134 · sec.gov
Prefer a blank slate with reverse DCF? Open the standalone DCF / reverse DCF for NMR